CDK2 and esophageal squamous cell carcinoma: Our data showed that FCL treatment obviously dropped the protein levels of CyclinE and CDK2/4/6 in both EC1 and ECA109 cells (Figure 2C), suggesting that FCL prevented G1 to S phase progression of ESCC cells.